Larimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q2 EPS of ($0.41), $0.07 better than the analyst estimate of ($0.48).

For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.